Pharmat ologtc al analysts of male rat sexual behav.~r NEUROSCI BIOBEHAV REV i1(4) 365-389, 1987--Pharmacological influences on male rat sexual behavior are reviewed m an attempt to tdentify neurotransmitters and their respective receptor types that regulate various factors comprising the behavmral pattern. Evidence is presented that" (1) serotonerg~c influence is generally inhibitory to sexual behavtor, although two receptor subtypes may lower ejaculatmn threshold, (2) dopammerg~c agomsts faohtate several aspects of copulatory behavmr and ea c optda gemtal responses; (3) noradrenerglc activity appears to increase sexual arousal; (4) cholinerglc agomsts facditate ejaculatton, or m some cases, delay or prevent ruination of copulation, (5) GABA agomsts mh~b~t sexual responses both ill and ex coptda, (6) opmte agonists appear to inhibit copulatmn and pemle reflexes, although antagomsts have mixed effects, (7) ACTH and MSH peptides promote copulatory behavmr and gemtal responses, (8) oxytocm facdltates er ~ opula pemle responses, but may contribute to postejaculatory refractoriness, and (9) long-term exposure to prolactm mh~b~ts sexual behavmr and pende responses. Although some progress has been made m tdentffymg neurotransm~tter-receptor effects on behavmral components, copulatory behavtor is complex and no drug has been found to affect only a smgle component Furthermore, drug speclfioty Is only relative Thus, a major means by which stermd hormones may influence behavior is by increasing or decreasing the synthesis, release, and/or effectiveness of certain neurotransmltters in specific neural locations. A second impetus for the study of the pharmacology of sexual behavior is that numerous clinically admimstered drugs have been found to have either beneficial or detrimental side effects on human sexual function. Application of the rapidly expanding knowledge and techniques of pharmacology to the regulation of sexual behavior may improve the efficacy and specificity of treatment for sexual dysfunction and may reduce unwanted side effects of drugs prescribed for other disorders. Use of animal models may help to elucidate these problems.
FOR years the study of sexual behavior focussed primanly on the hormonal mechanisms and neuroanatom~cal loci important for its control. However, several recent reviews have emphasized the interactions of steroid hormones with functional activity of neurotransmitters [146, 147, 172] . Thus, a major means by which stermd hormones may influence behavior is by increasing or decreasing the synthesis, release, and/or effectiveness of certain neurotransmltters in specific neural locations.
A second impetus for the study of the pharmacology of sexual behavior is that numerous clinically admimstered drugs have been found to have either beneficial or detrimental side effects on human sexual function. Application of the rapidly expanding knowledge and techniques of pharmacology to the regulation of sexual behavior may improve the efficacy and specificity of treatment for sexual dysfunction and may reduce unwanted side effects of drugs prescribed for other disorders. Use of animal models may help to elucidate these problems.
Since the literature addressing pharmacological influences on sexual behavior has expanded greatly in the past few years, a review of this work is in order. We shall limit our discussion almost exclusively to research on the laboratory rat, since that animal is the subject of most of the work in this area. Furthermore, we shall discuss only the research on masculine sexual behavior, with emphasis on the most recent work. We shall first describe the coital behavior of laboratory rats, as well as related tests of sexual function. We will then d~scuss the influences of several classes of drugs on elements of these behaviors. However, we should hke to begin with the caveat that drug selectivity is only relative. Therefore, one cannot draw firm conclusions regarding the specifioty of any type of neurotransmitterreceptor action for a gwen behavioral effect, especially when drug doses are large and only a few drugs are assayed.
DESCRIPTION OF MALE RAT SEXUAL BEHAVIOR
Copulatory behavior of the male rat is characterized by a series of mounts, with or without vaginal insertion, from the rear of the female, approximately once every 30 to 120 sec, that eventually culminate in ejaculation. The female responds to each mount with a lordosis response: a dorsoflexion of the spine and deflection of the tad to one s~de allowing vaginal access to the male. Typmally the male achieves vaginal penetration on 50 to 80 percent of his mounts. Introm~s-sion patterns (mounts with vaginal insemon) can be distinguished behaviorally from mounts without penetration by the presence of a deep thrust and a springing dismount. An ejaculation occurs after 6 to 12 intromissions, and is followed by a period of 4 to 8 minutes when the male is refractory to further copulatory activity, the postejaculatory interval. This pattern is repeated for 5 to 10 copulatory series, as the number of intromissions and latency to ejaculation at first tRequests for repnnts should be addressed to Daniel Bitran at present address. Untverslty of Connecttcut, Department of Psychology, U-20, 406 Cross Campus Rd., Storrs, CT 06268. [8, I1, 86, 117] [861 [144] [32]
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Conceptual Analysts of Components of Male Sexual Behavior
Common measures of copulatory activity have been categorized mto several hypothetical regulatory factors [31, 190] . A sexual arousal factor is typically measured by mount and mtromlssion latencles (time from the introduction of the female to the first mount and mtromlsslon, respectively). A measure reflectmg copulatory efficiency is the proportion of mounts which gain penile insertion, and ~s termed lntromlsslon ratio [139] , or sometimes "hit rate" [190] . A copulatory rate factor is comprised of the mterlntrom~sslon interval (mean interval between successive lntromissions preceding an ejaculation), ejaculauon latency, and postejaculatory interval. Finally, ejaculatory behavior is regulated by the introm~sslon count factor, and ~s measured as the number of intromissions preceding ejaculation. A hypothetical ejaculatory threshold is defined primarily as the number of lntromlsslons and latency to an ejaculation.
In summary, sexual behavior can be analyzed broadly into two major components: libido and potency. Libido ~s defined here as sexual arousal and is measured in terms of mount and intromission latencies. However, these measures are confounded by the erectile processes (i.e., potency) necessary for the successful execution of copulatory patterns.
Other tests have been devised which allow some separation of sexual motivation from potency. Sexual arousal can be assessed with mount tests following penile anesthetization [71] , which prevents penile insertion and ejaculation, whereas erectile potency can be measured in ex copula penile reflex tests [110] . Penile erections can be evoked from rats restrained in a supine position by retracting the preputial sheath and maintaining the sheath in a retracted position [110] . The relationship between the responses observed in the supine test and those occurring dunng copulatory behavior have been described [111, 192] . Briefly, intense erections that result in a flanng of the glans penis ("cups") are associated with the placement of the ejaculatory plug against the cervix. A tight fitting plug ensures adequate sperm transport and mhtbits plug displacement by another male [145] . Dorsiflexions of the glans penis ("flips") are associated with gaining a proper onentation for penile insertion during copulatory mounts [191, 192] . Seminal emissions are also observed during the supine test if the preputial sheath is left unretracted (E. R. Smith, personal communication). Thus, responses observed in the supine penile reflex test have correlates to penile responses occurring m copula.
Finally, administration of a number of drugs (discussed in detail below) has been reported to elicit signs of "sexual arousal" in the sexually naive, freely moving male rat, in the absence of a receptive female. Pelvic thrusting is observed accompanied by penile protrusion, genital grooming, and often, ejaculation. In addition, the frequent occurrence of stretching and yawning is observed These behaviors are termed the "penile erection/stretching-yawning syndrome" (PE/SYS). Since it is unclear whether ejaculation always occurs during PE/SYS, or if some episodes of penile erection occur without ejaculation, we will also refer to these behaviors collectively as PE/SYS.
Methodological Considerations
In discerning the effects of drugs on male sexual behavior, it is necessary to specify the meaning of facilitation and inhibition. Facilitation is sometimes demonstrated as an increase in the proportion of males engaging in copulatory be- Note. Abbrevmtlons are AMPT, alpha-methyl p-tyroslne. ICV. mtracerebroventncular. MPOA, medml preoptlc area. NA. nucleus accumbens, PE/SYS, penile erectmn/stretchlng yawmng syndrome, PVN, paraventncular nucleus. RDS-127. 2-N.N-dl-n-propylammo-4.7-dlethoxymdane, SN, substantta mgra. (-)3-PPP. (3-(3-hydroxyphenyl)-N-n-propylplperldme, 6-OHDA, 6-hydroxydopamme ~Followmg intra-MPOA rejection of 6-OHDA, see text for discussion ZPreferentml DA neurotoxm ff apphed w~th a noradrenerg~c reuptake blocker *Results have been attributed to an increase m 5-HT utthzat,on, see text for detads havlor or of those ejaculating (e.g., [139, 140] ). It sometimes refers to an increase in the number of ejaculations within a given time period (e.g., [121] ), or before sexual satiation is reached. It may also refer to an increase in copulatory rate or in intromission ratlo. Finally, several authors have defined facilitation as a decrease in the number of intromlsslons preceding ejaculation (e g., [8] ). However, although a reduction in mtromxssion frequency may be viewed as a facilitation of ejaculat=on in c oplda. It should be noted that such a reduction may actually impair the ability of the female to become pregnant [1], and thus may ultimately be viewed as a form of sexual dysfunction. Another consideration in determining the effects of drugs on male copulatory behavior is that a certain capacxty for motor function is reqmred. Thus, drugs may affect sexual behavior indirectly, as a result of primary impairment of motor ability or of induction of competing behavior patterns. It is therefore important to assess the effects of pharmacological treatment on locomotor activity independently of coital behavior.
MONOAMINES AND MALE SEXUAL BEHAVIOR A PRELIMINARY HYPOTHESIS

Increased Level~ of Monoamtne~ Inhibit Sexual Behavior
The earliest hypothesis concerning the neurochemlcal basis of male copulatory behavior stated that monoamines (the catecholamlnes, including dopamme, norepinephnne, and epinephrine, and the indoleamine, serotonin) play a generic inhibitory role in its expression. This hypothes,s was substantmted by experiments which showed that the most consistent effect of systemic administration of various monoamine oxidase (MAO) mhibitors (e.g., pargyhne) was a deficit in male copulatory behavior [75, 139, 141, 214] . For example, the number of animals lntromittlng and ejaculating was decreased by pargyline [214] and the number of intromissions, as well as ejaculation latency and poste.laculatory period were increased in animals that were copulating [75] . The functional effect of MAO inhibltors is to increase the hfespan of monoamines by preventing their intracellular degradation following reuptake. Th~s treatment results in an accumulation of all monoamines; thus behavioral effects of MAO inhibitors could be a result of increased activity of any one or combination of those transmitters. The only concluslon that can be made from these studies is that an increase in one or more of the brain monoamine levels inhibits copulatory behavior [73] .
Depletum of Monoamines" Contradictoo' Result~
Complementary evidence for the hypothesis that brain monoamines inhibit male sexual behavior is found in studies showing that drugs that deplete brain monoamines (e.g., tetrabenazine or reserpine) had a facihtatlve effect on male copulatory behavior [72, 74] . More specifically, reserpine decreased the number of intromlsslons prior to an ejaculation, as well as ejaculation latency
In contrast, other studies have shown that systemic administration of tetrabenazlne [54, 139] or reserpine [139] abolished copulatory behavior in intact, and castrated testosterone-treated males, respectwely. Thus, contradictory results have been found as a result of monoamine storage depletion. Furthermore, since reserpine and tetrabenazine deplete both serotonm (5-HT) and catecholamine levels, the resultant effect of these drugs on sexual behavior may be due to depletion of any one or combination of them.
SEROTONERGIC INFLUENCE ON SEXUAL BEHAVIOR
Dr,gs Affe~ tmg 5-HT Synthesis
Evidence implicating 5-HT as the primary monoamine inhibiting sexual behavior was subsequently reported (see Table I ) p-Chlorophenylalanlne (PCPA), a drug that inhibits 5-HT synthesis, was found to reverse the inhibition of sexual behavior by pargyline [214] . Furthermore, biochemical analys~s showed that pargyline produced a much greater increase in brain 5-HT levels than in brain catecholamine levels [214] . Thus, the behavioral effects were correlated with changes xn 5-HT, rather than catecholamine, levels.
There are numerous studies concerning the sexually stimulatory effects of the 5-HT synthesis inhibitor, PCPA (reviewed in [99] ). In groups of males, all receiving PCPA, a dramatic increase in male-to-male mounting occurred, a behavior rarely observed in control ammals [202, 203, 215] . The PCPA-mduced hypersexuality was found to be greatest at the time of maximal 5-HT depletion in the brain [215] . Heterosexual responses were also facilitated by PCPA; an increase in the number of males displaying mounting behav-Ior [142, 201] , decreases in ejaculation latency [5, 139, 197, 225] and postejaculatory period [148, 164] were observed. Overall, these studies suggest that 5-HT depletion is correlated with a facilitation of male sexual behavior.
Complementary evidence concerning the inhibitory role of 5-HT in male copulatory behavior comes from pharmacologic manipulations which increase brain 5-HT levels. This can be achxeved by an injection of 5-hydroxytryptophan (5-HTP), the direct precursor of 5-HT, following pretreatment with an extracerebral decarboxylase inhibitor and a MAO inhibitor. The rationale for pretreatlng with these enzyme inhibitors is to restrict the formation of 5-HT to the central nervous system, and to protect the newly formed transmitter from oxidative degradation. This regimen decreased the number of ammals mounting and mtromltting, and increased the mtromisslon latency of animals that did copulate [139, 143] . The inhibitory effects of 5-HTP were reversed by pretreatment with PCPA [142, 214] . A subeffective dose of 5-HTP, administered concomitantly with zimehdlne, a 5-HT reuptake blocker, prolonged both ejaculation latency and postejaculatory interval, and increased the number of intromlsslons preceding ejaculation [7, 12] . That these effects were specific to the serotonergic synapse was evidenced by the observation that metergoline, a 5-HT receptor blocker, antagonized the inhibitory effects of 5-HTP [7, 12] .
On the other hand, treatment with indirect 5-HT agonists (see Table I ) have been reported to induce PE/SYS in sexually naive male rats [32] . For example, PE/SYS was observed as a result of the systemic administration of 5-HTP, various 5-HT uptake mhibitors (e.g., zimelidine, fluoxetlne, citalopram, and ORG 6997), or a 5-HT releasing drug, fenfluramme. Thus, indirect 5-HT agonlsts inhibit Ul coptda sexual responses, but have resulted in the induction of ex (op,/a indices of sexual arousal (i.e., PE/SYS). The neural mechanisms underlying this discrepancy are not understood; however, it may be due to the differential involvement of 5-HT receptor subtypes mediating tn copula versus e.x c optda sexual responses (see below)
5-HT Agonists and Antagomst~
Another approach to the study of serotonerglc influence on male copulatory behawor is the administration of receptor agonists and antagomsts. According to the evidence reviewed above, one would expect that stimulation of 5-HT receptors should result in inhibition, whereas receptor blockade should facilitate sexual responses. However, the use of 5-HT receptor agonlsts has yielded evidence contradictory to the hypothesis that central 5-HT has an inhibitory action on male rat sexual behavior Conflicting results have been reported with the use of d-lysergic diethylamide (LSD), a purported receptor agonist. In low doses, LSD has been reported to facilitate several measures of copulatory behavior, including decreases in intromlssion latency and postejaculatory interval, and an increase in the proportion of animals displaying intromlssion patterns [41] . At higher doses, however, fewer animals mounted and intromitted, and their introm~ssion latencies and postejaculatory intervals were longer than in controls [41, 139] These discrepant findings can be resolved by the hypothesis that low doses of LSD preferentially stimulate autoreceptors, thereby inhibiting presynaptic release of transmitter [3] . However, the data concerning the pharmacological actions of LSD are unclear [67] , thereby making interpretations of its behavioral actions difficult.
Yet another discrepancy appeared when it was reported that the central 5-HT agonist, 8-hydroxy-2-(dl-n-propylamino) tetrahn (8-OH-DPAT), reduced the number of intromissions prior to an ejaculation, and shortened the ejaculation latency and postejaculatory interval [I 3]. Thus, rather than inhibiting masculine sexual behavior, a 5-HT receptor agonist increased copulatory rate and facilitated ejaculation. Two possible explanations for this discrepancy have emerged: (l) 8-OH-DPAT is an agonlst at a subset of 5-HT receptors that actually facilitate masculine sexual behavior, or (2) the drug is a mixed agonlst/antagonlst at 5-HT receptors. These hypotheses will be considered m turn.
Central 5-HT receptors have been differentially characterized into two major subtypes, 5-HT~ and 5-HT~. Whereas most classical serotonergic drugs bind readily to both subtypes, some newer drugs bind selectively to one subtype or the other (see [50] ), 5-HT, receptors have been further classified as either 5-HTt x (high affinity for spiperone) or 5-HT,~ (low affimty for spiperone). (5-HT.., receptors also have a high affinity for splperone, but are blocked by "classical" 5-HT antagonists (e.g., methyserglde), whereas 5-HTt receptors are not.)
8-OH-DPAT is generally considered to be a selective agonist at 5-HTLx receptors [162] . If 8-OH-DPAT were a selective autoreceptor agonist, then its facihtat~on of sexual behavior could be understood as a result of decreased endogenous 5-HT activity. There is some evidence that 8-OH-DPAT stimulates inhibitory autoreceptors [102, 106] located on cell bodies [116, 224] , rather than on axon terminals [222] . RDS-127 (2-N,N-di-n-propylamino-4,7-dimethoxylndane), a drug which binds with high affinity to 5-HT~ receptors [130] , has also been found to decrease intromiss~on frequency and ejaculation latency when administered systemically [64, 65] or intracerebroventncularly [59] . Thus, the facilitative effects of 8-OH-DPAT and RDS-127 on male copulatory behavior may be a result of decreased serotonerglc neurotransmlssion via the preferential stimulation of 5-HT~ x (auto?)receptors.
A facihtatlve role for the 5-HT._, receptor subtype in ejaculatory behavior recently has been suggested. Systemic administration of pirenperone or ketanserin, 5-HT., receptor antagonists, inhibited male sexual behavior [157] . For example, systemic administration of p~renperone decreased the number of sexual naive males mounting and introm~ttmg, and prolonged mount latency, intromission latency, and postejaculatory interval in sexually experienced male rats [157] . Furthermore, these same antagomsts impaired the ability of the 5-HT releasing agent, p-chloroamphetamme, to elicit ejaculation [186] . That 5-HT2 receptors are not revolved in 8-OH-DPAT's facilitative effects was demonstrated by Ahlenius and Larsson [8] , who showed that pirenperone was not effective in blocking 8-OH-DPAT-induced ejaculation. Therefore, two subtypes of serotonin receptors may facilitate sexual behavior of male rats: 5-HT~,~ and 5-HT2. Mendelson and Gorzalka [158] have suggested that the inhibitory effects of serotonergic drugs may be produced by 5-HTtH receptors, by the recently recognized 5-HT,c receptors [177] , or by an as yet unidentified subtype.
The second explanation of 8-OH-DPAT's facditative effects, that it is a mixed agonist/antagonist at 5-HT receptors, was suggested by Ahlenius and Larsson [9] . They had prewously demonstrated that the effects of 8-OH-DPAT could not be blocked by either the dopamine antagonist haloperidol [8] , or by the 5-HT antagonists methiothepin, metergoline, or pirenperone, which differentially affect 5-HT~ or 5-HT2 re- Note Abbreviations are DDC. diethyldithlocarbamate, DSP4, N-2-chloroethyI-N-ethyl-2-bromobenzylamme ceptors [7] . They concluded that 8-OH-DPAT seems not to act like a direct agonist at either 5-HTI or 5-HT2 receptors. However, 8-OH-DPAT did exhibit one characteristic of a 5-HT antagonist; it blocked, in a dose-dependent manner, the inhibition of sexual behavior by the serotonin precursor 5-HTP [9] . Lisuride too, has been reported to act as a mixed 5-HT agonist/antagonist [165] , and has been shown to reduce the number of intromissions and latency to ejaculation [11, 86, 117] . The mixed agonist/antagonist effects of a partial agonist could explain the "paradoxical" facilitative effects of both 8-OH-DPAT and lisuride, which also blocked the 5-HTP-induced inhibition. However, even if these drugs do act as partial agonists at a subgroup of 5-HT receptors, the ability of 5-HT2 antagonists to inhibit sexual behavior [157, 186] suggests that at least this subset of receptors may actively facilitate masculine sexual behavior. A final consideration in the discussion of serotonergic influence on copulation of male rats is the possible role of adrenergic mediation of, or interaction with, the serotonergic effects. Ahlenius and Larsson (to be published) found that, in contrast to the ineffectiveness of dopamlnergic and serotonergic antagonists in blocking the facilitative effects of 8-OH-DPAT and lisuride, (-)alpranolol and (-)pindolol, /3-adrenergic antagonists, did block these effects. It is important to note that these compounds have 5-HT1 receptor blocking properties [168] . Therefore, a reasonable conclusion is that the 5-HTI antagonistic activity of these compounds is responsible for the attenuation of 8-OH-DPAT-induced ejaculation. Support for this hypothesis awaits the use of a fl-adrenergic antagonist without serotonergic antagonist activity in its ability to block 8-OH-DPAT-induced facilitation of ejaculatory behavior.
Evidence implicating a noradrenergic-serotonergic interaction in the regulation of copulatory behavior was recently reported [86] . A depletion of central noreplnephrlne by means of DSP-4 (N-2-chloroethyl-N-ethyl-2-bromobenzylamine) treatment (a noradrenergic neurotoxin) blocked the reduction in ejaculation threshold by lisuride and by the serotonin agonist 5-MeODMT (5-methoxy-N,N-dimethyltryptamine).
In addition to the suspected role of 5-HTIA and 5-HT.., receptor stimulation on male copulatory behavior, the 5-HT,~ receptor subtype has been imphcated m the production of PE/SYS [32] . The putative 5-HTIB receptor agonist, mCPP (1-(Y-chlorophenyl)-piperazine) [204] , was found to be a potent inducer of PE/SYS. PE/SYS reduced by ORG 6997 was blocked by (-)pindolol and propranolol, /3-adrenoceptor antagonists with 5-HTI receptor blocking properties (see Table I ). In addition, butoxamlne and metaprolol,/31 and 132 receptor antagonists without 5-HT1 antagonistic activities, were ineffective in attenuating ORG 6997-induced PE/SYS. Thus, the attenuation of PE/SYS by (-)pindolol and pro- pranolol are most hkely a result of their 5-HT~ blockmg properties [32] . In contrast to mCPP, the 5-HT~ x receptor agonists, 8-OH-DPAT and 5-MeODMT, were ineffective. Doses of sptperone and plrenperone, which were selective for blockade of 5-HTI x and 5-HT._, receptors, were meffectlve m attenuatmg ORG 6997-induced PE/SYS. Together, these data suggest that stimulation of 5-HTI, receptor sites contribute to drug-induced PE/SYS [32] . Spinal mechamsms. Besides the apparent role of the ascending serotonergic projections in male copulatory behavior, descending serotonergm fibers to the spinal cord may be important for the regulation of sexual genito-pelvic reflexes.
Lo(ahzatum of 5-HT Lffect~ Ascending raphe axons
The sexually dlmorphic lumbosacral motor nuclei whose projections innervate the perineal muscles [52, 199] that control erectile reflexes [191] are themselves innervated by serotonerglc fibers presumably originating in brainstem nuclei [161] . Thus, intrathecal administration (i.e., in the subarachnoid space around the lumbosacral spinal cord) of 5-HT resulted in a dramatic reduction in the proportion of animals achieving pemle intromisslons; however, mounting behavior was unaffected [212] . Comparable injections of 5-HT into the brain (i.e., into the cerebral ventricles) decreased both mount and intromisslon rates [212] . Both treatment paradigms significantly decreased the number of rats that achieved an ejaculation. The authors suggested that the inability to achieve an ejaculation following intraventncular administration of 5-HT was due to a decrease in the approach tendencies of the male towards the female. After intrathecal administration, however, the failure to ejaculate may have been due to a decreased proportion of mounts which resulted in vaginal penetration. A similar decrease in intromlsslon ratio occurs after functional deafferentation of the penis, which impairs the abdity to locate the vaginal orifice [2, 135, 193] . Thus, spinal serotonerglc fibers may inhibit the transmission of penile sensory information and/or the motor nuclei regulating penile reflexes. Both influences are necessary for proper orientation and insertion of the penis.
The spinal serotonergic regulation of erectile and ejaculatory mechanisms was further implicated in a recent study investigating the effects of a direct 5-HT receptor agonlst (5-MeODMT) and a 5-HT reuptake blocker (zimehdlne) on ex ~opula penile responses [144] . The systemic administration of both agents reduced penile erections but stimulated seminal emission observed in a supine test. A spinal site of action was inferred since spinal transection eliminated zimelidlne's effects without altenng the 5-MeODMT-induced effects on penile responses. Thus, the direct receptor agonlst was still effective in spinal animals, whereas the reuptake blocker, which reqmres the integrity of presynaptic nerve terminals for ~ts actions, was without effect
hlterac tion of 5-HT and Gonadal Hormone.s
Several experiments have suggested an interaction of gonadal steroids with serotonerglc neurotransmission in the regulation of male sexual behavior. Castration of male rats has been reported to increase the levels of 5-HT in certain hypothalamic areas, including the medial forebrain bundle and ventromedial hypothalamic nucleus [220] . The demonstration that disruption of 5-HT synthesis also facilitated sexual behavior In recently castrated male rats given no testosterone [132, 207] suggests that one way in which testosterone might normally activate male sexual behavior is by reducing transmission at inhibitory, serotonergic synapses. Indeed, depletion of hypothalamic 5-HT was correlated with the activational effects of 5,7-DHT on sexual behavior [ 132] . In contrast, a similar study reported no relationship between hypothalamic 5-HT levels and copulatory behavior after intraventricutar 5,7-DHT treatment in castrated male rats [207] . Similarly, steady-state concentrations of 5-HT and 5-HIAA (5-hydroxyindoleacetic acid, the primary metabolite of 5-HT) in several hypothalamic regions, including the preoptlc area, anterior hypothalamus, ventromedlal hypothalamus, and suprachiasmatic nucleus, were unaffected by castration, at a time when sexual behavior was declining [51] . Thus, the relationship between hypothalamic 5-HT activity and male copulatory behavior is unresolved.
In summary, numerous experiments with indirect 5-HT agonists and antagonists have contributed to the conclusion that serotonin synapses inhibit male sexual behavior. However, recent evidence has accumulated that direct stimulation of certain 5-HT receptor subtypes lowers ejaculation threshold. It appears that full or partial agonists at 5-HT~ receptors decrease both ejaculation latency and the number of intromissions preceding ejaculation. 5-HTz receptors may also facilitate some aspects of copulatory behavior, while 5-HTtR receptors may contribute to drug-induced PE/SYS. There is contradictory evidence with regard to the influence of gonadal steroids on serotonergic activity. Finally, widespread axons ascending from raphe nuclei, as well as fibers descending to the lumbosacral spinal cord, have been implicated in the serotonerglc regulation of ejaculation and erectile mechanisms.
DOPAMINERGIC INFLUENCE ON COPULATORY BEHAVIOR
Clmt~ al Data
The importance of a dopaminerglc influence on human sexual function is well documented. Clinical reports have shown that dopamine (DA) agonists can alleviate impotence associated with renal failure [189] or diabetes [183] , and increases in libido have been reported as a result of 1-DOPA (precursor of DA) medication in Parkmson's disease patients [25, 46] . Furthermore, impotence, often reported as a side effect of neuroleptlcs in schizophrenic patients [104] , may be related to the inhibitory effects of the medication on dopaminergic neurotransmisslon.
EJJe~ ts of Catecholamme Pi ecur~or I-DOPA
The effects of indirect and direct DA agonists on male rat copulatory behavior have been documented by several laboratories (see Table 2 ). Early work suggested that DA may inhibit male rat copulatory behavior. Systemic administration of high doses of I-DOPA in sexually vigorous males was reported to slow copulatory rate, increase ejaculation latency and postejaculatory interval [103, 123] . However, high doses of I-DOPA increase the utilization of central 5-HT stores, as evidenced by decreases in brain 5-HT and increases in 5-HIAA [26, 55, 123, 170, 171] . Therefore, it is likely that the inhibitory effects of large doses of I-DOPA on male sexual behavior are an indirect result of greater 5-HT transmission.
On the other hand, 1-DOPA administered in lower doses has been reported to increase the proportion of sexually sluggish male rats [213] or castrated males treated with suboptimal doses of testosterone [139, 140, 143] that mounted, lntromitted, and ejaculated. In vigorous copulators, I-DOPA significantly decreased both ejaculation latency and the number of intromissions preceding ejaculation [176, 213] . I-DOPA is the precursor molecule for both DA and NE. That the effects of I-DOPA on male copulatory behavior were not due to an increase in noradrenergic neurotransmission was suggested by the observation that the noradrenergic (alpha-2) agonist, clonidine, had little effect on copulatory behavior at doses that did not affect motor capability ( [139] , but see [63] discussed below).
Dopamme Receptor Agonists and Antagonists
In accord with the facilitative effects of increased DA synthesis, systemic injections of apomorphine, a DA receptor agonist, dramatically reduced the number of intromissions preceding ejaculation [54, 61, 85, 176, 213] . The reduction in ejaculatory threshold induced by apomorphine was blocked by the DA receptor antagonists halopendol, pimozide, and sulplride [85, 176, 213] . Apomorphlne's effects on male copulatory behavior appear to be mediated by central, rather than peripheral DA receptors, since systemic administration of domperidone, a DA antagomst that does not cross the blood-brain barrier, was ineffective in blocking apomorphlne-lnduced facilitation of sexual behavior [85] . Together, these studies strongly suggest that enhanced transmission at central DA synapses facilitates many aspects of male copulatory behavior, including an increased proportion of males copulating to an ejaculation, and a reduction in the number of intromlssions and latency to ejaculation m sexually vigorous copulators.
L~[~'~ t~ o['Dopamtnergtc Agom,~t,~ on Male Copttlato O' Behal'im" Pre-oJ Po,~t,synaptt~ Re~ eptot A~ ttvatton '~
Recently a controversy has arisen as to the proposed mechanisms by which DA agomsts facilitate some aspects of male sexual behavior. Some investigators [22, 61, 64, 65, 85, 96, 169, 176] have proposed that the reduction m ejaculatory threshold by DA agomsts results from the selectwe activation of presynaptic autoreceptors, which decrease the release of endogenous DA, thereby reducing postsynaptic actlvlty This hypothesis was based largely on the observation that the doses of DA agonists that reduced e, laculatory threshold were lower than those that usually result in hyperactivity, a commonly accepted indication of postsynaptlc activation. Thus, inhibition of dopaminerglc neurotransmission was hypothesized to facilitate an ejaculatory mechanism. Additional support for the presynaptic origin of these effects was provided by reports that putative DA autoreceptor agonlsts also reduced the ejaculatory threshold m intact males [64, 65, 92, 169] . We shall first present the evidence in favor of the autoreceptor hypothesis, then discuss the problems with each piece of evidence, and finally present evidence against the hypothes~s.
Llsuride, an agonlst at both DA and 5-HT sites, has been reported to decrease both the time and the number of lntromissions preceding ejaculation in sexually experienced male rats [8, 11, 169] In addition, it restored copulatory behavior in nonmating castrated males [11] and males with medial preoptlc area lesions [108] . In another study, Hansen [107] reported that intrathecal m lectlons of hsunde also dramatically reduced the ejaculatory threshold. The systemically injected hsunde was reported to produce sedation [107, 169] , an effect commonly attributed to stimulation of DA autoreceptors. Therefore, the reduction in e laculatory threshold observed following llsunde administration was hypothesized to result from DA autoreceptor activation [169] . A problem with this interpretation is that Ilsuride's effects could not be mimicked (or blocked) by the DA antagonist haloperidol [8] If hsuride was selectively stimulating inhibitory autoreceptors, then one would expect that blockade of postsynaptlc DA receptors would produce similar behavioral effects.
As noted in the previous section, lisuride is now thought to be a mixed agonlst/antagonlst at 5-HT receptors, as well as an agonist at DA receptors Thus, serotonerglc synapses may mediate lisurlde's effects on copulatory behavior. A recent report has suggested that lisuride may affect male sexual behavior by interacting with alpha-2 adrenoceptors [93] . Systemic injections of yohimbine, an alpha-2 receptor antagonist (see below), potentiated male-to-male mounting behavior mduced by lisuride. Llsuride-lnduced mounting was blocked by clonidlne pretreatment, an alpha-2 adrenoceptor agonlst [93] . In addition, low doses of BHT-920, which are believed to preferentially activate DA receptors [15] , did not affect hsuride-lnduced mounting behavior [93] , whereas higher doses, believed to stimulate alpha-2 receptors [15] , antagonized mounting ehclted by lisuride [93] . Together, these data suggest that hsurlde's effects on mounting behavior may be related to its adrenerglc properties Low doses of hsuride have been reported to increase the incidence of penile erection and/or seminal emission in the absence of a receptive female (PE/SYS), and this effect was blocked by both the DA antagonists haloperldol and sulplride and the 5-HT antagonist methyserglde [22] . In contrast, higher doses of hsurlde decreased PE/SYS [22] . Thls type of blphastc dose-response curve has frequently been interpreted as evidence that the effects of the lower dose result from selective activation of autoreceptors, while the effects of the higher dose arise from stimulation of postsynaptlc receptors at the same synapse. Such an interpretatlon would favor the hypothesis that DA autoreceptors promote PE/SYS. In support of this hypothesis, low doses of the putative DA autoreceptor agonlst BHT-920 have also been reported to elicit PE/SYS, while higher doses (m the dose range believed to stimulate alpha-2 adrenoceptors [15] ) decreased this measure [92] . Furthermore, halopendol blocked the effects of low doses of BHT-920 [92] . Thus, DA receptors of some sort (possibly autoreceptors) do appear to influence ex copttla penile responses. However, the relationship of these responses (i.e., PE/SYS) to copulatory behavior has not been fully clarified.
RDS-127 is another drug that has both DA and 5-HT agonlst properties. Clark and his colleagues reported that RDS-127 reduced both ejaculation latency and intromlssions preceding ejaculation, and suggested that these effects resuited from selective DA autoreceptor stimulation [60, 64, 65] . In addition, RDS-127 induced seminal emission, but decreased the number of penile erections elicited in e.x copula supine tests [60, 65, 210] Intracerebroventncular injections of rather large doses (up to 600 /zg) of RDS-127 also increased the incidence of ex ~ opttla seminal emission and reduced ejaculation threshold m ~opula [59] .
Two lines of evidence mitigate against the inference that RDS-127 facilitated an ejaculatory mechanism in copula by acting selectively on DA autoreceptors. The first questions the selectivity for autoreceptors of the doses used; the second questions the role of DA, as opposed to 5-HT receptors. (I) Closer inspection of the dose dependent effects of RDS-127 reveals that, at the lowest dose tested (that which would presumably be most selectwe for autoreceptors), inhibition of several copulatory parameters was observed, including a decrease in intromlsslon ratio, and increases in ejaculation latency, interlntromlssion Interval, and postejaculatory interval [65] . These findings are inconsistent with the hypothesis that autoreceptor activation facilitates male sexual behavior. Furthermore, the faclhtative effects were observed with doses of RDS-127 that were previously shown to activate postsynaptic DA receptors [21] . Therefore, if RDS-127 facilitates an ejaculatory mechanism via a DA receptor, it ~s the postsynaptic receptor, rather than the presynaptic autoreceptor that appears to be the more likely candidate. (2) RDS-127 was recently reported to bind with high affinity to the 5-HT~ ~ receptor [59, 130] Furthermore, the reduction m eJaculation threshold ~s quahtatlvely slmdar to the effects of 8-OH-DPAT and hsurlde, both of which have been shown to interact with 5-HT, x receptors In contrast to the effects of RDS-127 on eJaculation threshold m copula, the effects of RDS-127 on ea copula seminal emission were blocked by pimozlde, a DA receptor antagomst [60] Thus, as with lisurlde, stimulation of DA (auto'S)receptors by RDS-127 may enhance ev copttla seminal emission; however, both drugs probably affect copulatory behavior through actions on 5-HT,~ receptors [60] .
A recently synthesized compound, 3-PPP (3-(3-hydroxyphenyl)-N-n-propyl-plpendlne), was inttmlly thought to be a selective DA autoreceptor agonlst [ 115] This drug decreased ejaculation latency and mtromisslon frequency of copulating male rats [169] . and induced PE/SYS [101] . Both of these effects were attributed to action on DA autoreceptors Furthermore, the effects of 3-PPP on PE/SYS were blocked by the DA antagomst haloperldol, confirming an action on some sort of DA receptors [101] .
3-PPP is a racemlc mixture of (+) and (-) enantlomers. The (-) enantiomer has been shown to be an autoreceptor agomst and a postsynapt~c receptor antagonist [115] . Thus, both of its pharmacological activities act to decrease dopamlnergic neurotransmlsslon. On the other hand, the (+) enantiomer is an autoreceptor agonlst at low doses, and stimulates postsynaptlc receptors at higher doses [115] . If the facilitation of eJaculation in and ex copula by 3-PPP were due to inhibition of DA neurotransmission by autoreceptor stimulation, then the (-) enantlomer should be more effective than the (+) enantlomer. In fact, the opposite has been observed. (+)3-PPP reduced the ejaculatory threshold m tests of copulatory behavior [6] , and induced PE/SYS [ 101] ; (-)3-PPP was Ineffective in both paradigms. Furthermore, the reduction in eJaculation threshold by (+)3-PPP occurred only at higher doses [6], which have been reported to increase locomotor activity, suggesting postsynaptlc receptor activation [173] Therefore, instead of supporting the "autoreceptor hypothesis" of sexual facilitation, studies using the enantiomers of 3-PPP actually support a role for postsynaptlc DA receptors in thxs regard.
Finally, a study employing an extensive range of doses of the selective De DA receptor agonist (a DA receptor that is either negatively linked or not linked to adenylate cyclase), LY163502. found that systemic inJection of the very lowest doses (0.025 to 10 ng/kg) increased eJaculation latency, while higher doses (25 /xg to 2.5 mg/kg) decreased that measure [94] . Some of the relatively higher doses that decreased eJaculation latency were still lower than those that produced putative "'autoreceptor'" effects, e g., suppressed striatal DOPAC and HVA levels (DA metabolltes) or locomotor behavior (minimum effectwe dose for these measures was 1 /xg/kg) (references in [94] ).
If one accepts the biphasic dose-response curve as indicative of autoreceptor versus postsynaptlc receptor activation, then stimulation of autoreceptors m neural c~rcults regulating sexual behavior may lmpa|r copulatory mechanisms, while stimulation of postsynaptlc receptors in these circuits may facditate those mechanisms In comparison with effects on locomotor activity, the entire dose response curve for copulatory behavior may be shifted to the left; i.e., doses that affect this behavior may be one or more orders of magnitude lower than those inducing hyperactivity or stereotypy. A similar example from our research wdl be presented in the following section
In conclusion, studies reporting facditatlon of some aspects of male copulatory behawor by purported DA autoreceptor agonists are difficult to interpret, since these agents have been shown to affect 5-HT neurotransmisslon and/or to activate postsynaptic DA receptors. The observation that these agonists do not result in hyperactivity or stereotypy is the focal point of the hypothesis that the effects on sexual behavior must therefore be attributed to selective stimulation of autoreceptors. Other interpretations, however, cannot be ruled out: (1) 5-HT~.x receptors may mediate the effects. (2) The population of DA receptors affecting male copulatory responses may be located in an area of the brain which is more easily accessible to systemically administered drugs. (3) The sensitivity of these DA receptors and/or their physiological efficacy may differ from those involved m locomotor responses.
Localization of Dopamhlergtc lzffec ts on Male SeMtal Behavior
Whereas the effects of hsunde and RDS-127 on copulatory behavior may be attributed to a serotonerglc influence, other drugs, including apomorphine and I-DOPA, have been shown to affect copulation by means of dopaminergic systems, since their effects were blocked by DA antagonists [85, 139, 213] . Several brain areas have been proposed as possible s~tes of these dopaminergic effects. In order to be considered here, an area must both receive a dopaminerg~c projection and be implicated, by lesion or electrical or steroid hormone stimulation experiments, in the control of male sexual behavior.
The nigrostriatal tract, ascending from the zona compacta of the substantm nigra to the neostnatum, is a major candidate for dopaminerglc effects on sexual behavior. Electrolytic lesions of the substantm nigra have been reported to mcrease mount, intromission and ejaculation latencies [49, 149] , as well as the postejaculatory interval [149] . Neurochemical lesions using the selective catecholamme neurotoxin, 6-hydroxydopamine (6-OHDA), significantly lengthened only the postejaculatory interval [149] , suggesting that damage to nondopaminergic cells contributed to the prolongation of contact and ejaculation latencles by males with electrolytic lesions to the substantia nigra. However, the reported correlation between striatal DA levels and other copulatory parameters following electrolytic lesions of the substantia mgra [49] (i.e., depletion of strlatal DA levels was correlated with prolonged mount and ejaculation latencles), suggests that the stnatal DA system may contribute to the regulation of several aspects of copulatory behavior On the other hand, the effects of striatal DA depletion may be indicative of a general reduction In responsiveness to environmental stimuh, rather than a specific effect on copulatory behavior, since similar lesions of the mgrostriatal tract have been shown to suppress ingestive behaviors [228] , intracranial self-stimulation [16] , and active avoidance [66] . In hne with this suggestion, we have found that microinjectlons of apomorphine directly into the caudate nucleus had no effect on copulation [121] .
Other potential sztes of dopaminergic regulation of male sexual behavior are the nucleus accumbens and lateral septal area; both are major targets of mesolimbic DA axons. Castration has been reported to reduce the concentration of DA and its metabohtes in the nucleus accumbens and septal area, but not in the caudate-putamen [14] . Hormone replacement raised the levels of DA and/or its metabolites to normal in both these areas (but with contradictory results, see [29] ) Furthermore, implantation of dihydrotestosterone into the lateral septum restored copulation in non-mating castrates given sub-optimal doses of estrogen [30] . These findings suggest a role for the mesolimbic DA system in the regulation of male copulatory behavior. Some support for this role was provided by our finding that microinjections of apomorphine into the nucleus accumbens produced a doserelated decrease in intromission latency; however, this effect was of marginal statistical sigmficance (p=0.058) [121] .
Another potential site for dopaminergic influence is the medial preoptic area (MPOA). The importance of the MPOA for male copulatory behavior has long been recognized [100, 113] . Furthermore, a small group of DA axons of the mcertohypothalamic tract innervates the MPOA [44] . We have recently rep.orted that several measures of male rat copulatory behavior were affected in a dose-dependent fashion by mzcroinjections of apomorphine into either the lateral ventricle (LV) or the MPOA [121] . Intraventricular injections of a low dose of apomorphine (0.2 /zg) significantly reduced the number of ejaculations, copulatory rate, and intromission ratio. Higher doses of apomorphine (0.5 and 2 /zg) injected into the LV facditated the same measures that were impaired by the low dose. Such a biphasic doseresponse curve is frequently taken as an mdicat~on that the effect of the lower dose ~s produced by selective stimulation ofautoreceptors, while that of the higher dose(s) results from postsynaptic receptor activation. Thus, reduction of DA neurotransmisslon by autoreceptors appeared to Inhibit copulation, while stimulation of postsynapt~c receptors seemed to facilitate it.
Of four brain areas tested (caudate nucleus, nucleus accumbens, lateral septum, and MPOA), effects of microinject~ons into the MPOA most closely resembled, and in some cases, were more pronounced than the dose-dependent effects seen after LV injections. Specifically, the facditatlve effects of MPOA injections achieved h~gher levels of statistical sigmficance, and more measures were facilitated than w~th LV injections. On the other hand, inhibitory effects of MPOA injections were not statistically sigmficant, whereas those of LV injections were significant Two possible explanations of the differential effectiveness of LV and MPOA mjectlons are: (I) The MPOA is responsible for the facditat,ve effects, while another structure is responsible for the inhibitory effects. (2) The facihtative effects result from activation of postsynaptic receptors in the MPOA, while the Inhibitory effects resulted from selective stimulation of autoreceptors, which decreased DA neurotransmlssion. In th~s case, a dose of apomorphme injected into the LV would have been diluted by cerebrospmal fluid, thereby reducing its concentratzon at the site of action. Thus, a low dose would be made even more selective for autoreceptors by this dilution; the same dose injected directly mto the MPOA might be sufficient to stimulate some postsynaptic receptors, thereby canceling some of the inhibitory effects. By s~milar reasoning, the facilitative effects of higher doses should be greater if injected directly into the active s~te, rather than into the LV.
A series of experiments designed to decide between these alternative interpretations has recently been completed [42] . If stimulation of postsynaptic DA receptors in the MPOA facilitates a copulatory mechanism, and if reduction of that postsynaptic stimulation by "autoreceptor selective doses" of apomorphine ~mpa~rs copulation, then s~milar reduction of postsynaptlc stimulation, produced by 6-OHDA lesions of dopammerglc terminals in the MPOA, should also impair sexual behavior. Contrary to this hypothesis, 6-OHDA lesions of the MPOA failed to impair copulation; however, biochemical analyses of post-lesion preoptic tissue and subsequent pharmacological challenges suggested that a double compensation had occurred at those synapses [43] . First, the standard intracranial 6-OHDA regimen (8/zg in 2/zl, injected over 8 min) produced only a 23 percent depletion of DA. Other studies have reported that 80 to 90 percent depletions are necessary to induce changes in motivated or locomotor behavior [227, 229] . Furthermore, whereas DA levels were depleted, levels of the DA metabolite, DOPAC (3,4-dihydroxyphenylacetic acid), were virtually identical to those of controls [43] . Thus, the remaining DA terminals had apparently increased their output to compensate almost exactly for the loss of some terminals. That this increased DA turnover was an ~mportant compensatory mechanism was demonstrated in another experiment in which the synthesis inhibitor, alpha-methyl p-tyroslne (AMPT), impaired sexual behavior after 6-OHDA lesions, but not before the lesions [43] . A second compensatory mechanism apparently involved denervatlon supersensitivity. A dose of apomorphine (0.2 /xg) injected into the MPOA previously had not significantly affected copulation [ 121 ] ; however, it facilitated that behavior after 6-OHDA lesions [43] , apparently by activating supersensitive receptors. This same dose mjected into the LV had previously impaired copulation [121] , presumably by activating autoreceptors selectively; after the 6-OHDA lesion, however, this dose in the LV no longer impaired the behavior [43] . Finally, an even lower dose (0.1 /zg) injected into an intact (control) MPOA did impair copulation; the same dose injected into a 6-OHDA-treated MPOA faded to impair copulation [43] . This series of experiments suggests that: (1) The facilitative effects of intraventricular (and MPOA) injections of apomorphine were mediated by postsynaptic receptors in the MPOA. (2) The inhibitory effects of low doses of apomorphine injected into the LV were mediated by reductions in DA neurotransmission in the MPOA, presumably mediated by autoreceptors on DA terminals there (see [136] ). (3) The dose range of apomorphme injected into the MPOA that affects sexual behavior is at least an order of magnitude lower than that previously shown to affect locomotor behavior, when injected either into the nucleus accumbens [124, 127, 221] or the caudate-putamen [219] . Furthermore, since the drug was microinjected dlrectly into brain tissue, accessability to systemic circulation was not a factor determining sensitivity to the drug. Thus, it would appear that either the preoptic DA receptors exhibit greater affin|ty for agonists (Kd) or they are present in greater number (Bmax), or their physiological efficacy Is greater than receptors mediating locomotor changes.
A recent study has implicated the paraventricular nucleus of the hypothalamus (PVN) as an important area in the regulation of pende responses observed m ex copula tests (i.e., PE/SYS) [156] . Microinjections of apomorphine, LY171555 (quinplrole, a specific Do. DA receptor agonist), and (+)3-PPP into the PVN produced episodes of PE/SYS which were antagonized by prior systemic treatment with sulpinde (a specific Do. DA receptor antagonist) or SCH-23390 (a specific DI DA receptor antagonist). Similar injections of DA agonists into the lateral borders of the POA, ventromedial and dorsomedial hypothalamus, neostriatum, nucleus accumbens, and substantla nigra were ineffective.
In summary, lesions of the nigrostriatal system have resulted in deficits of copulatory arousal and copulatory rate measures. The specificity of these lesion effects to male sexual behavior remains to be determined, despite the reported correlation between striatal DA levels and sexual performance. The MPOA is an important site for the regulation of male copulatory behavior, and DA terminals of the incertohypothalamic system may contribute to the regulation of copulatory rate. Finally, the PVN has been recently implicated as a neural site for the generation of drug-induced PE/SYS.
It is important to mention that the neural site(s) mediating the decrease in ejaculatory threshold observed following the systemic administration of DA agonists has not been determined and is (are) probably not in the brain, since apomorphine injection into the cerebral ventricles did not reduce ejaculation threshold [43, 121] . Further experimentation should investigate the effects of intrathecal administration of apomorphme on male sexual behavior, since a spinal site of action may be a hkely candidate for the ejaculatory inducing effects of apomorphine.
Interaction of DA and Testicular Hormones
Since both DA agonists [121] and testosterone (T) [70] , applied locally to the MPOA, have been found to facilitate male sexual behavior, it is possible that at least some of T's effects may be mediated by alterations of DA activity m the incertohypothalamic tract.
An early study found that castration decreased the DA content of the anterior hypothalamus, including preoptlc tissue [80] . In contrast, castration was reported to have mcreased DA turnover rate in the whole hypothalamus [35] . These studies are difficult to interpret since the hypothalamus contains populations of DA neurons which may differ in their response to gonadectomy. Indeed, a recent study has shown differential hormonal effects on DA metabolism of incertohypothalamic and tuberoinfundibular neurons [105] . Two weeks following castration, DA turnover decreased in the MPOA, but increased m the median eminence (ME), a terminal bed for tuberoinfundlbular neurons. T replacement in castrated males decreased the rate of turnover in the ME and increased DA turnover in the MPOA [105] . Therefore, circulating T levels sufficient to maintain copulatory behavior in the male rat [68] were found to stimulate DA activity in the MPOA. Estradiol (E2) implants m the MPOA are as effective as T in activating copulatory behavior in castrated male rats [57] . Furthermore, E2 injections in hypophysectomized male rats increased DA turnover in the MPOA [137] . Thus, both T and E2 have been found to stimulate copulatory behavior and DA metabolism in the MPOA.
In contrast to studies reviewed above, Simpkms and colleagues have found that systemic T administration in castrated male rats decreased DA turnover rate in the MPOA [206] . Furthermore, T or dlhydrotestosterone (DHT) implants into the MPOA of castrated animals produced a similar suppression in DA metabolism [205] . It is important to note, however, that DHT, the alpha-reduced metabolite of T, was ineffective in activating male sexual behavior in castrated rats when implanted into the MPOA [125] . The factor(s) underlying these diametrically opposed results is (are) not apparent. The only obvious difference between the studies is the strain of rats used. It IS interesting that the behavioral studies demonstrating a facilitative influence of intra-MPOA injection of DA agonists on male sexual behavior [42, 121] employed the same strain of rat which responds to castration with a decreased DA turnover in the MPOA [105] .
NORADRENERGIC INFLUENCES ON MALE SEXUAL BEHAVIOR
Pharmacological manipulations of noradrenergic systems have resulted in alterations of sexual behavior. Malmnas [139] reported that inhibition of noreplnephrine (NE) synthesis by FLA-63 increased the rate of mounting in castrated male rats treated with suboptimal doses of T. In contrast, inhibition of NE synthesis in intact males with diethyl-dith~ocarbamate was reported to have increased mount and intromlssion latencies [150] . In addition, this treatment significantly lengthened ejaculation latency and postejaculatory interval [150] . Depletions of central NE, by DSP4 injections [109] or electrolytic lesions of the locus coeruleus [150] , similarly prolonged the postejaculatory interval.
Results from a series of expenments [62, 63, 130] have suggested that alpha-adrenerg~c receptors specifically affect sexual arousal. For example, yohimbme (which mcreases NE transmission by blocking inhibitory alpha-2 adrenoceptors) was reported to increase the number of mounts after genital anesthet~zatmn, to increase the percentage of sexually naive males mounting, intromltting and ejaculating, and to decrease the latency to mtromisslon [62] . In another study, yohlmbme faclhtated several copulatory rate and ejaculation threshold measures, including decreased ejaculation latency, postejaculatory interval, mtercopulatory interval, and mtromlssions preceding ejaculation, whde the alpha-2 agonist, clonidine (which decreases noradrenergic transmission), was found to decrease the number of males ejaculating [63] In addition, the alpha-I receptor antagonist, prazosm, slowed copulation by increasing intromission and ejaculation latencies and increasing postejaculatory interval [63] . Finally, a recent report demonstrated that three drugs (yohimblne, imiloxan, and idazoxan) which were found to increase sexual arousal, all bound with high affinity to alpha-2 receptors [130] . These authors suggested that drugs that increase noradrenerg~c neurotransmission dramatically increase sexual arousal.
In summary, evidence for a noradrenergic facilitation of sexual arousal has been presented (see Table 3 ). Increased noradrenerglc activity, resulting from blockade of inhibitory alpha-2 adrenoceptors, increased the number of males copulating, increased the number of mounts in tests with genital anesthetizatlon, and decreased mount and intromlssion latencies. Decreased noradrenergic transmission, produced by selective lesions, stimulation of alpha-2 adrenoceptors, inhibition of synthesis, or blockade of alpha-l (postsynaptic) receptors, impaired these same measures In addmon, some measures of copulatory rate and ejaculation threshold have been facihtated by enhanced noradrenerglc transmission.
CHOLINERGIC INFLUENCE ON COPULATORY BEHAVIOR
Chohnergt~ Agomsts and Antagoni~t.~
Early studies of chohnergic influence on male rat sexual behawor reported suppression of such behavior by both agonists (nicotine, in high doses, and physostlgmine, an acetylcholinesterase inhibitor) and antagonists (atropine and scopolamine) [41, 133, 209] . However, the high drug doses used interfered with motor behavmr and autonomic functions, so the specificity of those effects is questionable. The only facihtative treatment, a relatively low dose of mcotine, increased the number of ejaculations and reduced mtromission frequency, ejaculation latency, and postejaculatory interval; however, it also increased motor activity and brain 5-HT levels [209] . Since the behavioral facihtation was correlated with the accumulation of 5-HT, it seems hkely that reduced serotonergic activity at least contributed to the nicotinic enhancement of sexual behavior.
A more recent study employing the selective muscarinic agonist oxotremonne reported reductions in intromlssion frequency and ejaculation latency at doses that did not produce motor impairment [10] . The specificity for muscannic receptors was confirmed by the blockade of these effects by the muscarinic antagonist scopolamine. Furthermore, the failure of methscopolamine (which does not cross the blood-brain barrier) to block these effects indicated their central origin.
Brain Lo~ ahzatton of Cholinergi~ Influence
As alluded to earlier, the importance of the MPOA for mascuhne sexual behavior has been demonstrated repeatedly, in several experimental paradigms. Furthermore, both muscanmc receptors [76] and choline acetyltransferase (CHAT') [138] , the enzyme that synthesizes acetylcholine (ACh), are present in the preoptic area (POA). In a series of expenments we compared the effects on sexual behavior of mlcroinjections into the LV and POA of two cholinergic receptor agonists, carbachol and oxotremonne, and one antagonist, scopolamine [119, 120, 122] .
Intracerebroventricular m~croinject~ons of both carbachol, which stimulates n~cotlmC and muscarimc receptors, and oxotremorlne, which is more selective for muscarimc receptors, decreased sexual arousal, i.e., increased mount and intromisslon latencles [119, 120] . In addition, oxotremorine slowed the rate of intromitting [120] . Ventricular microlnject~ons of the muscarlnlC antagonist, scopolamine, also delayed the onset of copulation [122] , as did the agonlsts.
A very different pattern of results was seen with preoptic microinjectlons, the primary effect of which was to decrease the number of intromisslons preceding ejaculation. While carbachol did slightly increase intromlssion latency [119] , that experiment utilized vertical cannulae, some of which pierced the lateral ventricle. The injected drug may have diffused up the cannula track and gained access to the ventricular circulation in some animals. In a second experiment, oxotremorlne was injected through angled cannulae, none of which impinged on any ventricle. Oxotremorlne rejected via angled cannulae and restricted to the POA did not prolong intromlsslon latency [120] . On the other hand, both carbachol and oxotremorine decreased the number of introm~s-sions preceding ejaculation. Thus, the main effect of cholinerg~c agomsts on the POA appears to be a facilitation of ejaculatory behavior as measured by a significant decrease in the number of intromissions preceding ejaculation.
Microinjections of the muscarinic antagonist scopolamine, restricted to the POA, produced a dose-related decrease m percentage of animals intromitting and ejaculating [122] . In an additional experiment, oxotremorine, scopolamine, a mixture of the two, or vehicle were microinjected into the POA through cannulae angled to miss the ventricles (Hull, unpublished observations). As before, oxotremorine alone decreased mtrom~ssion frequency; scopolamine alone decreased the percentage of animals copulating; and oxotremorine plus scopolamine was not different from vehicle. Thus, not only did the antagonist block the agomst's reduction in mtrom~ssion frequency, but the agonist also blocked the antagonist's reduction in percentage of animals copulating, apparently by competing w~th the antagonist for receptors.
From these experiments, we suggest that some cholinerglc actwatlon in the POA is critical for normal copulation; blocking muscannic receptors there resulted in a decreased propomon of animals copulating; among those that did at least mount, fewer gained intromission or ejaculation. On the other hand, enhancing cholinergic activity in the POA served only to decrease the number of intromissions preceding ejaculation (i.e., decreased ejaculation threshold). In contrast to the differential effects of agonists and antagonist in the POA, both types of drug micromjected into the LV only delayed the onset of copulation. Most animals so treated did eventually copulate, displaying normal parameters.
In summary (see Table 4 ), moderate doses of chohnerglc agonists, rejected either systemically or directly into the POA, have been found to reduce the number of mtromlssions preceding ejaculation. On the other hand, microinjection of a chohnergic antagomst into the POA decreased the number of animals copulating. Thus, at least some cholinergic activity in the POA appears to be necessary for copulatlon, while moderate increases in preoptlc chohnergic transmission decreases ejaculation threshold. Both cholinerglc agonists and an antagonist, injected into the ventricles, delayed the initiation of copulation. Similarly, large doses of both agonlsts and antagonists, injected systemically, decreased the number of animals copulating. Together, these studies suggest that separate chohnergic mechanisms may contribute to the initiation of copulation and ejaculation threshold.
GAMMA-AMINOBUTYRIC ACID (GABA) Ab'D MALE SEXUAL BEHAVIOR
GABA IS an inhibitory neurotransmitter which is found ubiquitously, but is unevenly distributed in the mammahan central nervous system [84, 187] . In addition to GABA's well documented role in stnato-mgral function [198] , high concentrations of GABA have been reported in the MPOA of male rat brains [83, 216] .
Several recent experiments have shown a regulatory influence of GABAergic neurotransmission on male rat copulatory behavior and penile erectile function (see Table  5 ). During the postejaculatory refractory period, the ~.crebrospinal fluid concentration of GABA increased dramatically [185] . This correlational study is suggestive of an inhibitory influence of GABA on copulatory activity. In agreement with this hypothesis are findings that systemic administration of several GABAergic drugs inhibited sexual behavior [4] . In castrated male rats given sub-optimal doses of T, the proportion of animals mounting and intromltting decreased after injections of baclofen or THIP (4,5,6,7-tetrahydrolsoxazolo[5,4-C]pyrldln-3-ol), potent GABA receptor agonlsts. However, systemic injection of bicuculline, a GABA receptor antagomst, did not affect any copulatory measure. In fact, concomitant injection of blcuculline with a non-effective dose of THIP produced strong inhibitory effects on sexual behavior.
These results are difficult to interpret in that an antagonist potentiated the effects of an agonlst. A possible explanation lies in the fact that GABA receptors are heterogeneous. There are at least two types of GABA receptors: GABA,x are activated by GABA and some agonlsts, including THIP and muscimol, and are blocked by bicuculhne and picrotoxin; GABAn are also activated by GABA, but not by most GABAmimetic compounds, and are unaffected by bicuculline. Baciofen is a potent GABA~3 agonist, with little or no activity at GABAa binding sites [47] . Specific GABA~ antagonists have yet to be developed. Thus, the potentiation of THIP's inhibitory effect on sexual behavior by bicuculline was interpreted [4] as resulting from the blockade of pre-and postsynapt~c GABA~ receptors (see [53] ). The presynaptic blockade resulted in the endogenous release of GABA which then preferentially activated GABA~ sites, since the GABA sites were occupied by bicuculline. This hypothesis suggests that THIP may have some effect on the GABAa receptor (in addition to ItS stimulation of GABAA receptors), and that the inhibition of male sexual behavior by GABA is mediated by GABAt~ receptor activation.
However, GABAA sites may also inhibit sexual behavior. A series of experiments has demonstrated potent stimulatory effects on copulatory behavior resulting from the stereospeclfic blockade of GABA~ receptor sites in the MPOA [87] [88] [89] [90] . Intra-MPOA injection of (+)bicuculline resulted in a dramatic reduction of the postejaculatory interval, as well as a virtual elimination of the ultrasonic vocalizations normally emitted dunng the sexual refractory period [90] . The intracranial injection of bicuculline also hastened the onset of sexual behavior in non-copulating castrated rats given T replacement [89] . Injection of musclmol into the MPOA of intact sexually experienced male rats resulted in a significant suppression of sexual behavior, expressed in a decreasing proportion of animals mounting, lntromitting, and ejaculating [88] . Thus, blockade of GABAergic transmission at suspected GABA x receptor sites in the MPOA facihtated the onset of copulatory behavior following ejaculation, as well as the reinstatement of copulatory behavior in castrated animals given T.
The influence of GABA on erectile reflexes has also been investigated (R. L. Leipheimer and B. D. Sachs, submitted). Systemic injection of the GABAn agonist baclofen (1 and 2 mg/kg) resulted in a dose-related decrease in the proportion of male rats displaying erections in a supine penile reflex test. Interestingly, baclofen, at those doses, was without effect on copulatory behavior. Systemic injections of THIP or bicuculhne did not affect penile reflexes or copulatory behavior.
Since GABA has been detected in the dorsal horn of the lumbosacral spinal cord [69] , and the presence of GABAt~ receptors has been described there as well [48] , a follow-up study was conducted in order to determine the effects of spinal baclofen injections on penile erectile responses. Intrathecal injections of baclofen aimed at the lumbosacral spinal cord produced inhibitory effects on erections comparable to those observed after systemic injection (D. Bitran and B. D Sachs, unpublished observations). Specifically, 0.2/xg baclofen increased erection latency and reduced the total number of erections. Higher doses of baclofen (0.4 and 0.8/zg) decreased the number of animals displaying penile erections. Slight inhibitory effects on copulatory behavior were also observed following the administration of the highest dose of baclofen (0.8 p.g), including increased ejaculation latency which resulted from a greater number of mounts without penile insertion. Intrathecal injections of baclofen aimed at the thoracic spinal cord did not affect penile responses in or ex copula. Interestingly, the dose-response curve of baclofen on penile reflexes was shifted to the right following an ejaculation (i.e., doses were less effective). The inhibitory effects of 0.2 and 0.4/.Lg baclofen on penile erections were not in evidence following an ejaculation. However, copulatory potentiation of penile reflexes was not observed following a higher dose (0.8/zg) of baclofen. Thus, an ejaculation may have desensitized the spinal GABAt~ receptors that mediate baclofen's inhibition of penile reflexes. The facilitation of penile responses in a supine test by a previous ejaculation has been demonstrated previously [129, 174, 195] . Copulatory experience immediately preceding an ex copula reflex test dramatically reduced the onset of penile responses. It has been inferred that copulation removes a source of supraspmal inhibition. Presumably, intrathecai baclofen ts less efficacious in inhibiting penile reflexes once supraspinal inhibitory influences are absent.
In summary, GABA has been imphcated as an inhibitory neurotransmitter in the regulation of copulatory behavior and penile erectile responses. Stimulation of presumed GABA.x sites in the MPOA decreased the number of animals mounting, intromitting, and ejaculating, while blockade of GABAA sites dramatically decreased the postejaculatory interval and facilitated reinstatement by testosterone of copulation after castratlon. Stimulation of GABA~ sites in the lumbosacral spinal cord inhibited ex copula penile reflexes.
NEUROPEPTIDES EFFECTS ON SEXUAL BEHAVIOR
Recently, much research has focused on the putative neurotransmitter/modulator function of peptides originally identified in non-neural t~ssues, such as the pituitary hormones prolactin, oxytocin, and the pro-op~omelanocortin derivatives, mcluding adrenocortlcotroplc hormone (ACTH), alpha-melanocyte stimulating hormone (MSH), and betaendorphm (reviewed in [128] ). Although the focus of much of thts work has been on the central nervous system distribution and neuroendocnne and autonomic homeostatic functions, effects of such peptides on learning and memory (reviewed m [153] ) and maternal behawor (e.g., [178] ) have also been demonstrated. In the followmg section, we will briefly review the effects of endogenous opiates, ACTH, MSH, oxytocin, and prolactm on male sexual behavior, with special reference to their possible d~rect action on the central nervous system (see Table 6 ).
Opiates
Systemt(ally administered agomsts and antagonist~.
There is general agreement that opiate agomsts impmr male rat copulatory behavior. A review of this hterature has recently been pubhshed [182] . For example, morphine has been reported to decrease the proportion of intact males copulating [114, 151, 166] . Lower doses were found to decrease the number of mounts and ejaculations of recently castrated males, but not of intact male rats [134] .
There is less agreement concerning the effects of antagonists on copulation On the one hand, naloxone and/or naltrexone appeared to facihtate copulation by increasing the percentage of mtact males copulating [97, 151] or ejaculating [167] , and by decreasing mount, mtromlssion, and ejaculation latencles, and/or mtromissions preceding ejaculation [151, 167, 180] On the other hand, naloxone appeared to have inhibitory effects, m that it increased the postejaculatory interval [197] and decreased the number of mounts and ejaculations by recently castrated males [134, 163] . The suggestion has been made that opiate antagomsts may impair sexual behavior of recent castrates by blocking its natural reward value, mediated by endogenous opiates [134] . Alternatively, exogenous opiates may decrease copulation by substituting for its intrinsic reward value.
An interaction of opiate and DA systems recently has been described in the control of pemle erection/seminal emission (PE/SYS). Specifically, naloxone potentmted PE/SYS induced by the DA agonists apomorphme [33] , or N-n-propylnorapomorphine (NPA) [91] . Naloxone by itself was reported to have either "modest" [91] or no effect [33] on PE/SYS. On the other hand, morphine blocked both spontaneous and dopaminerglc drug-induced PE/SYS [33, 91] . Furthermore, the DA antagonist haloperidol prevented the stimulant effects of NPA, naloxone, and naloxone plus NPA on PE/SYS [91] , suggesting that naioxone's effect, m the absence of haloperidol, was a potentiation of a dopaminergic effect.
Localization ofoptate effects.
Several studies have imphcated central, as opposed to peripheral, sites for opiate influences on copulation. The endogenous opiate,/3-endorphin, micromjected into the LV, produced a dose-dependent decrease in the proportion of males copulating, and increased the mount latency of those that did [151, 159, 160] . Similar effects were reported for micromjections of the long lasting synthetic opmte, D-ALA-met-enkephalinamide (DALA) [179] , and of morphine [151, 159] . The importance of opiate receptors for this effect was confirmed smce it was antagorazed by systemically injected naloxone [179] or naltrexone [160] . Morphine micromjections mto the MPOA decreased the mean number of ejaculattons per ammai, and increased the postejaculatory interval; similar mlcroinjections into the cerebral ventricles slowed the rate of mtromlssions and decreased intromlsslon ratio [24] . In accord with these findrags, mtra-MPOA mjectlons of naloxone decreased ejaculation latency and postejaculatory interval [24] .
Opiate mechamsms in the spinal cord appear to influence ejaculation threshold (i.e., the number of intromisstons precedmg an ejaculation) [226] . An mtrathecal injection of morphine, which preceded copulatory behavior by 1 hour, mcreased the number of intromlssions prior to ejaculation, whde naloxone mlcroinjected 10 minutes before a test decreased intromtsslon frequency. Furthermore, systemically administered naloxone blocked the morphine-reduced mcrease m mtrom~ss~on frequency.
It is interesting to note that systemically administered opiate agonists and antagonists have been reported to influence both ejaculation threshold (intromission frequency and ejaculation latency) and sexual arousal (mount and intromission latency and proportion of animals copulating). Intracramal m~croinjections, for the most part, have been reported to affect sexual arousal, whereas mtrathecal rejections affected only ejaculation threshold. Thus a hypothesis which awmts further experimentation is that systemically administered drugs influence sexual arousal through neural circmts within the brain, while they mfluence ejaculation threshold vm spinal mechanisms.
ACTH and MSH Pepttde~
ACTH and alpha-MSH are two of a group of peptides cleaved from a common precursor molecule, prooplomelanocortin. MSH consists of amino acid residues 1-13; ACTH of residues 1-39. Whde the entire ACTH peptide is reqmred to stimulate adrenocortlcal secretion, shorter fragments are active in the brain [128] .
Micromjection of ACTH,_24 or MSH into the cerebral ventricles of rabbits and rats elicited intense bouts of PE/SYS [38] . Furthermore, m copula tests of sexually experienced males revealed that ejaculation latency was significantly reduced after mtracranial rejections of ACTH. However, copulatory behavior of sexually sluggish males was not improved by such treatment [38] .
Contrary to the facilitative effects of ACTHI-24 on OF MALE SEXUAL BEHAVIOR 381 PE/SYS and copulatory behavior of sexually vigorous male rats, the intracramal injection of ACTH,_,o was reported to increase intromission and ejaculation latenc~es and to prolong the postejaculatory interval in castrated rats gwen a threshold dose (50/zg) of testosterone proprtonate (TP) [45] . Closer inspection of the behav,oral data reveals that the mean ejaculation latency of controls was less than 1 mmute, whde ACTH ~_,,, increased this latency to approxlmately 3 minutes. Thus, the administration of ACTH~_t,~ seemed to have normalized the ejaculat|on latency. Animals given a higher dose of TP (200 p.g) were not adversely affected by ACTH~_,,. Caution must therefore accompany assertions that ACTH ~_,,, is inhibitory to male rat copulatory behavior, since prolongation of ejaculation latency was observed only in ammals given submaxtmal doses of TP. Furthermore, some lengthening of such a short ejaculat,on latency would probably be advantageous to ensure a successful pregnancy
Ill.
Systemlc admlmstratlon of ACTH or MSH does not affect sexual behawor, suggesting that central, rather than perlpheral, mechanisms mediate thelr effects. Furthermore, the latency of PE/SYS was reduced from 30-60 minutes, after intraclsterna[ m~crolnject,on, to less than 7 minutes when the peptide was injected into the thlrd ventricle [98] . Thus, hypothalamlc structures ]mlng the third ventricle may mediate ACTH-induced PE/SYS MPOA ]eslons [40] and castration [38] abolished the sexual response to ACTH. Thus, test~cular androgens play a permisslve role in ACTH-mduced PF,/SYS However, adrenal hormones are not imphcated, since MSH is devold of adrenocorticotroplc act~vlty and yet, is a potent agent in ehcltlng PE/SYS [38] .
The mechanisms whereby ACTH elicits PE/SYS are presently unknown. However, ACTH and MSH peptldes have been hypothesized to act as endogenous antagomsts of opmtes [35, 37] The basis for thls hypothesls, with regard to PE/SYS, is that (l) ACTH results m a withdrawal syndrome m morphlne-dependent rats, mc[udlng PE/SYS [37, 39] , and (2) the effects of ACTH on PE/SYS are completely antagorazed by morphine [184] Thus, there may be a functlonal balance between ACTH peptldes and opiates m the regu]atlon of PE/SYS.
O.~ytocmelgt~ lnJlm, m e on Se vual Behav,~r
Several studies have investigated the role of oxytocm in male sexual behavior Increased plasma levels ofoxytocm m men have been detected in association with exposure to erotic stimuli [217] and ejaculation [175] . A recent study has reported increased plasma oxytocm during sexual arousal and ejaculation/orgasm, resulting from self-stimulation, in both men and women [56] . The authors interpreted their findings In terms of oxytocln's role in facilitating both sperm and egg transport by actwating smooth muscle contractions of the reproductive tract Animal studies have likewise demonstrated a correlative increase in plasma oxytocm concentration followmg sexual activity (eg., [211] ). Several experiments have reported faclhtatwe effects of systemic oxytocm injections on copulatory behavior Intravenous injection of oxytocin decreased ejaculation latency and increased ejaculation number in rabbits [154] , though slmdar mject,ons m rats had no effect on copulat,on [133] . However, m another study, mount and mtrom~ss~on latencies were reduced, as were the number of mtrom~sslons and latency to ejaculation following a systemic mject~on of oxytocln in sexually experienced male rats, the incidence of mounting behavior in sexually sluggish male rats was not affected [20] In a recent study, an increase in cerebral spinal fluid concentration of oxytocin was reported following ejaculation in the rat [118] . These findings suggest that oxytocinergic projectlons within the central nervous system may participate in the regulation of coital behavior [118] . In support of this hypothesis, intracranial injections of oxytocin have been reported to affect copulatory behavior, but with conflicting results. A low dose of oxytocm (1 ng) into the lateral ventricle mimicked the facdltative effects on sexual behavior observed following systemic admxmstratlon [20] ; however, higher doses (250 and 500 ng) were found to increase mount and mtromission latencies, and to prolong the postejaculatory refractory period [211] . In a follow-up study, electrolytic lesions of the parvocellular division of the PVN, cell bodies of which project to extrahypothalamic neural regions (reviewed in [208] ). abolished the postejaculatory mcrease m CSF oxytocln concentration, and also prolonged mount and intromission latencies, but decreased the postejaculatory interval [118] . The reported increase m contact latenctes following intracranial rejections of oxytocm and electrolyt,c lesions of the PVN are difficult to reconcile. However. the opposite effects of these manipulations on the postejaculatory interval suggest that oxytocinergic cell bodies of the PVN (and/or their projections) may participate in the sexual refractoriness following an ejaculation
Other effects of oxytocin on sexual responsiveness have also been reported. Intracerebroventricular (ICV) micromjectlon of an endogenous oxytocln-hke peptlde extracted from hypothalamic tissue [18] , or of synthetic oxytocm [17, 18] produced a dose-dependent increase in e.t copula PE/SYS Oxytocin-lnduced PE/SYS was blocked by the oxytocm antagonist, d(CH,)~Tyr(Me)-[Orn"]vasotocin [19] . PE/SYS observed following ICV administration of oxytocin was replicated by microlnjectlons mto the PVN of the hypothalamus, and the CAt field of the htppocampus [155] . The anatomical specificity of oxytocin-induced PE/SYS was noted in the lack of effect of similar mlcrolnjections into the lateral septum, caudate nucleus, ventromedlal nucleus, supraoptic nucleus, and preoptlc area [155] . It remains to be determined whether intra-PVN injections of oxytocm also affect copulatory behavior. Such an investigation may clarify the relationship, if any, between PE/SYS and male copulatory behavior.
Prolat tin and Male Sexual Behavior
Prolactin (PRL) ~s an anterior p~tmtary hormone that has many effects on male reproductive organs and copulatory behavior Short-term exposure (5 days or less) to elevated PRL levels has been shown to enhance sexual arousal by decreasing mount and introm~ssion latencies [82] However, long-term exposure has been found to depress both sexual arousal and potency of men [23, 181, 200] and male rats ( [27, 58, 79] reviewed in [81] ) The existence of PRL-containmg neurons m hypothalam~c areas important in the regulation of male copulatory behavior [95, 218] , and the possibility of the retrograde transport of PRL from the pituitary to the brain via the hypophyseal portal system [34] suggest that PRL may act directly on hypothalamic tissue to produce its effects on sexual behavior.
Several potential endocnnological changes have been ruled out as explanations for hyperPRL-induced deficits. For example, elevation of plasma PRL in the male rat does not affect circulating T level, testicular weight, or fertihty [28, 152] . That hyperPRL suppresses male rat copulatory behavior without affecting serum T levels suggests that the deleterious effects of hyperPRL on sexual behavior are not the result of altered testicular function Similarly, increased adrenocortical activation has been ruled out as a contributing factor [77] , though at least some corticosterone may be necessary for PRL-mduced defic|ts [223] .
Two recent studies [58, 79] have sought to determine whether deficits in sexual arousal or in potency are related to hyperPRL-induced impairment of copulatory behavior. The induction of hyperPRL by injection of minced PRL secreting tumors resulted m a significant suppression of penile erections ehcited in a supine test beginning 34 days after tumor inoculation [58] . In contrast, hyperPRL was found to decrease the number of erections as early as 7 days after pttmtary transplant [79] . The differences in the animals' sensitivity to hyperPRL's effect on erectile function may be straindependent. The latter study employed Fisher rats, which unhke other strains of rats (e.g., Long-Evans, SpragueDawley, Wsstar), do not d~splay spontaneous erections in a supine test. Thus, baseline response m these animals was observed following copulation, which normally facilitates the expression of penile reflexes [129, 174, 195] .
In copulatory tests, hyperPRL ammals displayed a decreased intromission capacity [78] . Likewise, a significant reduction in the number of penile flips was observed in ex copula supine tests [79] ; such penile flips appear to facilitate vaginal mtromission [ 112, 191 ] The inhibitory effects of elevated PRL levels on erectile potency appear to be medmted by central nervous tissue [79] . The suppression of penile reflexes in hyperPRL was reversed after transection of the spinal cord. Therefore, the inhibition of penile reflexes observed in hyperPRL animals may be exerted by as yet unidentified supraspmal site(s) [79] Sexual motivation was also inhibited in hyperPRL animals; mounting rates after penile anesthetlzat~on were significantly reduced, although this effect first appeared 28 days after pituitary transplantation (as compared to the deficits in erectile responses noted in these ammals 7 days after transplantation) [79] . Thus, the results suggest that deficits in sexual motivation may be secondary to a deficit in erectile function.
Elevated levels of PRL have been shown to affect the metabolism of hypothalamlc monoammes, including DA Recently, it has been demonstrated that hyperPRL induced by systemic injections of estradlol decreased the activity of |ncertohypothalamlc DA fibers innervating the MPOA [I 37]. Since neurons of the mcertohypothalamic DA system have been implicated m the regulation of male copulatory behavior [42, 121] and are stimulated by the presence of testosterone [105] , we suggest that high PRL levels may suppress copulatory behavior, m part, by inhibiting dopaminerglc activity in the MPOA. In contrast to this hypothesis are findings by Kalra and colleagues [126] who reported that hyper-PRL, induced by rejection of pituitary tumors, stimulated DA turnover in the MPOA, and that this effect was negatively correlated to the animals' sexual performance. That is, increasing plasma PRL level was associated with an mcreased DA turnover in the MPOA as copulatory behavior deteriorated. A notable difference between these studies is the degree of hyperPRL. Whereas estradiol administration [137] resulted in moderate hyperPRL (61 ng/ml), inoculation with PRL-secretmg tumors [126] resulted in a 1000-fold increase in plasma PRL levels (1186 ng/ml). As has been prewously suggested [81] , such long-term exposure to pathological PRL levels may result in a down regulation of DA receptor systems. Thus, an increased DA turnover rate might be viewed as a compensatory mechanism in hght of such hyposensitwity. To date, however, biochemical data substantiating this hypothesis have not been presented.
In summary, many of the studies of neuropeptide influences on male sexual behavior have centered on opiate systems. Most of these have concluded that opiate agomsts impair copulatory behavior and ex copula penile responses. However, opiate antagomsts have been reported to have both facihtative and inhibitory effects on copulation. Intracerebral administration of opiate agonlsts and antagomsts has affected measures of sexual arousal, while intrathecal administration has affected ejaculatory threshold.
Intracerebral injections of ACTH and MSH peptides have elicited PE/SYS and have lowered m copula ejaculation latency. These effects were dependent on an intact MPOA and testlcular hormones Furthermore, morphine antagonized ACTH-mduced PE/SYS, suggesting a functional interaction between ACTH pepttdes and opiates m the regulation of PE/SYS.
Oxytocm injected systemically was found to decrease ejaculation latency and postejaculatory interval Intracramal injections of oxytocm have produced conflicting results. Injection into the PVN or into the CAt region of the hlppocampus elicited PE/SYS; similar injections into several other sites were ineffective
Relative short-term hyperPRL may enhance sexual arousal. However, long-term exposure has consistently been found to depress both sexual arousal and penile reflexes. Prolactm's effects may be medmted in part by alterations of DA activity in the MPOA; however, controversy still surrounds the direction and interpretation of these alterations
CONCLUSIONS AND DIRECTIONS FOR FUTURE RESEARCH
In describing the effects of various neurotransmitters on male sexual behavxor, we have considered separately each of the transmitters, several potential sites of action, and individual measures of sexual function. Because of the complexity of the behavior and of Its neural mechanisms, it is necessary to manipulate variables independently. Several strategies have been utlhzed m the work reviewed here: (I) Pharmacological analysis has been used not only to differentiate one transmitter from the rest, but to discriminate receptor subtypes within the same transmitter "system." In addition, some behavior effects are dose-dependent, with one range of doses facilitating and another inhibiting a given behavioral measure. (2) Anatomical analysis has shown that a given drug applied to two or more different sites may produce location-specific effects. (3) Hormonal analysis has shown that a drug may ehclt one effect when animals are in a given hormonal state, and another effect or no effect at all when the hormonal state is altered (4) Finally, alteration of the test situation may reveal very different behavioral effects. For example, somewhat different neural mechanisms may affect tn copula and e.r copula tests of potency. The relationship between these measures is not yet clear.
While scientific analysis reqmres a dlssectlon of factors regulating sexual behavior, all of these influences exist in nature in an integrated pattern. Most of the neural sites ~m-phcated in these studies are characterized by reciprocal mterconnectlons w~th one another and by rich connections with other hmb~c, brain stem, and spinal nuclei, so that ac-tivtty in one site influences that m numerous other sites. Thus, the pharmacological influences reviewed here may extst m "parallel" or m "series" circuits. Furthermore, although ~t is convenient to dtscriminate sexual arousal, for example, from copulatory rate or ejaculatton threshold, a gxven stimulus or drug may affect more than one factor, by acting at one or more sites. There are two challenges in this work; the first is to ~solate and manipulate ind~wdual variables, and the other Is to understand how the variables work together to regulate reproductive behavior. A rich database now exists describing the effects of various drugs on sexual behavior. The available information is at present insufficient to achieve the latter goal; however, our understanding of the neurochemical regulatton of male sexual behavior is growing as a result of the mcreasmg sophistication with which pharmacologtcal agents are used as behavioral tools. 
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